Welcome to our dedicated page for Acm Research SEC filings (Ticker: ACMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ACM Research, Inc. (ACMR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ACM is a NASDAQ‑listed supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, and its filings offer detailed insight into its operations, financial performance and corporate structure.
Among the key documents, investors can review Form 10‑K annual reports and Form 10‑Q quarterly reports, which describe ACM’s semiconductor process equipment business spanning cleaning, electroplating, stress‑free polishing, vertical furnace processes, track systems, PECVD, and wafer‑ and panel‑level packaging tools. These reports typically discuss revenue drivers, contributions from its principal operating subsidiary ACM Research (Shanghai), Inc., and risk factors relevant to its markets and listings.
Frequent Form 8‑K current reports from ACM detail material events such as quarterly financial results, preliminary revenue and shipment ranges, backlog disclosures from ACM Shanghai, and capital raising activities at ACM Shanghai under STAR Market regulations. These filings often incorporate the full text of related press releases, providing official context for operating and financing updates.
Users can also locate Form 4 insider transaction reports, which disclose purchases and sales of ACMR equity by directors, officers and other insiders, as well as proxy materials that address governance matters and executive compensation. Stock Titan’s interface surfaces these filings with AI‑powered summaries that explain the significance of long and technical documents, highlight key changes across reporting periods, and make it easier to interpret complex sections of 10‑K, 10‑Q and 8‑K reports.
With real‑time updates from EDGAR and AI‑generated highlights, this page helps investors and analysts quickly understand what ACM Research reports to regulators about its semiconductor equipment and advanced packaging business.
Tracy Liu, a director of ACM Research, Inc. (ACMR), exercised 15,000 fully vested stock options on September 17, 2025, at a $1 exercise price, creating 15,000 shares of Class A common stock. The same day, the reporting person sold 15,000 shares at $33.00 per share pursuant to a Rule 10b5-1 trading plan adopted March 6, 2025. After these transactions, Ms. Liu beneficially owned 110,772 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Liu on September 19, 2025.
The reporting person, Jian Wang, exercised a fully vested stock option to acquire 30,000 shares of ACM Research Class A common stock at an exercise price of $5.60 per share and concurrently sold 30,000 shares under a Rule 10b5-1 trading plan at $35.00 per share. Following these transactions, the report shows beneficial ownership of 253,158 shares, down from 283,158 shares before the transactions.
The filing states the option was previously issued and fully exercisable and that the sales were effected pursuant to a 10b5-1 plan adopted on May 20, 2025. The form identifies the reporting person as an officer and notes an officer/subsidiary leadership role in ACM Research (Shanghai), Inc.
Insider activity at ACM Research (ACMR): Senior Vice President Sotheara Cheav exercised a stock option on 09/18/2025 to buy 10,000 shares of Class A common stock at an exercise price of $13.89 per share and simultaneously sold 10,000 shares at $35.00 per share under a Rule 10b5-1 trading plan adopted May 15, 2025. Following these transactions the reporting person beneficially owns 100,002 shares and holds options covering 56,250 underlying shares, with a portion of those options vesting through May 2026 and monthly thereafter. The Form 4 was signed on 09/19/2025 by an attorney-in-fact.
ACM Research, Inc. (ACMR) Form 144 notifies the SEC of a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney on 09/18/2025, with an aggregate market value of $1,050,000 and 64,180,965 shares outstanding. The filing states the shares were acquired the same day by stock option exercise and paid in cash. The filer represents no undisclosed material adverse information. The filing also discloses two recent sales by the same person in August 2025: 30,000 shares on 08/22/2025 for $900,012 and 30,000 shares on 08/25/2025 for $960,000.
Form 144 notice for ACM Research, Inc. (ACMR) reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $350,000 and an approximate sale date of 09/18/2025. The shares were acquired on 09/18/2025 by stock option exercise from the issuer and paid for in cash. The filer discloses prior sales by the same person: 11,152 common shares sold on 08/22/2025 for gross proceeds of $334,560. The filing includes the required representation that the seller does not possess undisclosed material adverse information.
Form 144 notice for ACM Research, Inc. (ACMR) reports proposed and recent sales of common stock by an insider. The filer intends to sell 15,000 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $495,000 and an approximate sale date of 09/17/2025. The same 15,000 shares are shown as acquired by stock option exercise on 09/17/2025 with payment in cash. The filing also discloses a prior sale of 15,000 common shares by Tracy Dong Liu on 07/15/2025 for $450,000 in gross proceeds. The notice includes the standard representation that the seller certifies they possess no undisclosed material adverse information and a signature attestation regarding accuracy.
ACM Research, Inc. (ACMR) reporting person David H. Wang, who is CEO, President and a director, disclosed multiple transactions on September 3-4, 2025. Mr. Wang exercised 130,000 stock options (70,000 on 09/03/2025 and 60,000 on 09/04/2025) at a $1 exercise price, each option fully vested and exercisable and underlying the same number of Class A shares.
He also sold a total of 130,000 Class A shares across those dates in several trades under a Rule 10b5-1 trading plan adopted on November 29, 2024, with weighted-average sale prices reported: $26.73 (66,057 shares), $27.31 (3,943 shares) and $26.44 (60,000 shares). After these transactions Mr. Wang reported beneficial ownership of 742,708 Class A shares directly and various indirect holdings through family trusts and relatives summing in disclosures (examples include 620,001 shares by the Wang-Chen Family Living Trust).
ACM Research (ACMR) Form 144 notice reports a proposed sale of 60,000 common shares through Morgan Stanley Smith Barney on 09/04/2025 with an aggregate market value of $1,586,508.00. The shares were acquired and to be sold following a stock option exercise on 09/04/2025 and payment was made in cash. The filing notes 64,180,965 shares outstanding. It also discloses a recent sale by Hui Wang of 70,000 shares on 09/03/2025 for $1,873,711.00. The filer certifies they are not aware of any undisclosed material adverse information.
ACM Research, Inc. (ACMR) filed a Form 144 reporting a proposed sale of 70,000 common shares through Morgan Stanley Smith Barney LLC, scheduled approximately on 09/03/2025 on NASDAQ with an aggregate market value of $1,873,711.00. The filing shows these shares were acquired and paid for on 09/03/2025 by exercise of a stock option, with payment in cash to the issuer.
The notice states there were no other sales by the reporting person in the prior three months. The filer certifies they are unaware of any undisclosed material adverse information about the issuer. The document provides broker details and confirms the transaction source as an option exercise rather than a gift or third-party purchase.
FAQ
What is the current stock price of Acm Research (ACMR)?
What is the market cap of Acm Research (ACMR)?
